Orchestra BioMed Holdings Inc(OBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1 | Insider Own | 31.12% | Shs Outstand | 60.1M | Perf Week | 11.33% |
| Market Cap | 0.37B | Forward P/E | - | EPS next Y | 0.68% | Insider Trans | -0.12% | Shs Float | 41.4M | Perf Month | -2.09% |
| Enterprise Value | 0.34B | PEG | - | EPS next Q | -0.4 | Inst Own | 46.07% | Short Float | 6.17% | Perf Quarter | 53.02% |
| Income | -0.06B | P/S | 11.45 | EPS this Y | -36.61% | Inst Trans | 7.29% | Short Ratio | 7.68 | Perf Half Y | 52.63% |
| Sales | 0.03B | P/B | 18.94 | EPS next 5Y | 4.97% | ROA | -74.47% | Short Interest | 2.55M | Perf YTD | 46.75% |
| Book/sh | 0.32 | P/C | 3.33 | EPS past 3/5Y | 20.91% -164.92% | ROE | -397.3% | 52W High | -6.31% ($6.50) | Perf Year | 68.7% |
| Cash/sh | 1.83 | P/FCF | - | Sales past 3/5Y | 111.62% - | ROIC | -59.4% | 52W Low | 76.01% ($3.46) | Perf 3Y | 32.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.31% | Gross Margin | 98.64% | Volatility(W/M) | 4.42% 6% | Perf 5Y | -38.24% |
| Dividend TTM | - | EV/Sales | 10.54 | Sales Y/Y TTM | 986.14% | Oper. Margin | -181.36% | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.24 | EPS Q/Q | 25.18% | Profit Margin | -186.3% | RSI (14) | 58.32 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.26 | Sales Q/Q | -89.47% | SMA20 | 5.58% ($5.77) | Beta | 0.54 | Target Price | $12.43 |
| Payout | - | Debt/Eq | 2.41 | Earnings | 2026/8/10 | SMA50 | 6.96% ($5.69) | Rel Volume | 0.83 | Prev Close | $5.99 |
| Employees | 86 | LT Debt/Eq | 2.38 | EPS/Sales Surpr. | 3.06% -36.09% | SMA200 | 34.53% ($4.53) | Avg Volume(3M) | 0.33M | Price | $6.09 |
| IPO | 2020/8/4 | Option/Short | Yes/Yes | Trades | 2331 | Volume | 274,571 | Change | 1.67% |
🫀 A US-based company developing cardiovascular treatment technologies through a partnership-driven biomedtech model. Its lead pipeline is an atrioventricular interval modulation therapy targeting uncontrolled hypertension, advancing clinical development and commercialization through collaborations with global medical device companies.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded about as much as usual. That is 83% of its average volume.
OBIO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -36.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,145. Peers typically go for $1,217.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -38.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 46.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #248 of 594 in the industry
Based on market cap of $366M.
ZURA#246 Zura Bio Ltd $371M PER - 
RLMD#247 Relmada Therapeutics Inc $367M PER - OBIO#248 Orchestra BioMed Holdings Inc $366M PER - 
SPRY#249 ARS Pharmaceuticals Inc $364M PER - 
KYTX#250 Kyverna Therapeutics Inc $362M PER - 
FAQ
What kind of company is OBIO?
OBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OBIO?
The market cap of OBIO is approximately $366M, ranking 3,440 within its sector.
What is the 52-week high and low for OBIO?
OBIO has recorded a 52-week high of $6.50 and a low of $3.46.
